Use of a Flavanol Glycoside for Suppressing Activation of Stellate Cells
This invention relates to the usage of a natural compound for suppressing the
activation of stellate cells. Particularly, this invention relates to the usage of a
naturally derived flavanol glycoside for suppressing activation of pancreatic stellate cells (PSCs).
Administering a composition comprising a therapeutically effective amount
of Eruberin A.
For suppressing the
activation of stellate cells
A method 5 of preventing, alleviating or treating pancreatic tumors or
pancreatic tumors related diseases includes administering a composition comprising a
therapeutically effective amount of Eruberin A. The Eruberin A may be extracted from
Pronephrium penangianum.
Patent Number: US20140348965A1
Application Number: US13899713A
Inventor: Bian, Zhaoxiang | Tsang, Siu Wai | Zhang, Hongjie | Chen, Yegao | Lu, Aiping | Chan, Albert Sun-Chi | Xu, Hongxi | Chen, Shilin | Yang, Dajian
Priority Date: 22 May 2013
Priority Number: US20140348965A1
Application Date: 22 May 2013
Publication Date: 27 Nov 2014
IPC Current: C07H000108 | A61K00317048 | A61K003612 | C07H0017065
US Class: 424763 | 514027 | 536008
Assignee Applicant: Hong Kong Baptist University
Title: USE OF A FLAVANOL GLYCOSIDE FOR SUPPRESSING ACTIVATION OF STELLATE CELLS
Usefulness: USE OF A FLAVANOL GLYCOSIDE FOR SUPPRESSING ACTIVATION OF STELLATE CELLS
Summary: The method is useful for: suppressing activation of stellate cells present in an internal organ of a subject who is human, where the internal organ comprises pancreas, liver, kidney or lung; preventing, alleviating or treating pancreatic tumors or pancreatic tumors related diseases, where the pancreatic tumors or pancreatic tumors related diseases include pancreatic ductal adenocarcinoma (all claimed); and treating chronic pancreatitis. Test details are described but no results given.
診斷/治療
癌症/腫瘤
2013.05.22
Filed
A61/BZ/Erub/US01
香港